ArticleOphthalmology and therapy2026
A Multimodal Approach to Open-Angle Glaucoma with Travoprost Intracameral Implant and Minimally Invasive Glaucoma Surgery with or Without Concurrent Cataract Surgery.
Article in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study aimed to characterize reductions in intraocular pressure (IOP) and the need for topical IOP-lowering medications in eyes undergoing implantation of a travoprost implant (iDose TR®; Glaukos) and either trabecular micro-bypass stent (iStent infinite®; Glaukos) implant or canaloplasty with or without cataract surgery in eyes with open-angle glaucoma (OAG).
methodsAdults undergoing the procedures of interest with ≥ 3 months of postoperative follow-up were included. The primary outcomes were changes in mean IOP and topical medication use from baseline to 3 months postoperatively. Analyses were conducted in the overall cohort and stratified by surgical context (with and without concurrent cataract surgery) and minimally invasive glaucoma surgery (MIGS) modality (iStent infinite and canaloplasty), resulting in four subgroups: iDose TR + iStent infinite with phacoemulsification, iDose TR + iStent infinite, iDose TR + canaloplasty with phacoemulsification, and iDose TR + canaloplasty.
resultsData from 107 eyes were analyzed. Overall, mean (standard deviation) IOP decreased from 19.0 (5.9) mmHg at baseline to 15.3 (4.6) mmHg at month 3 (p < 0.0001). In the phaco+ subgroup (66 eyes), mean IOP decreased from 17.5 (4.0) mmHg at baseline to 14.3 (2.4) mmHg (p < 0.0001) at month 3; in the phaco- subgroup, (41 eyes), mean IOP decreased from 21.6 (7.6) mmHg at baseline to 16.8 (6.5) mmHg (p = 0.001) at month 3. At month 3, topical medication-free rates were 59.4% overall, 67.7% in the phaco+ subgroup, and 46.3% in the phaco- subgroup. Similar reductions were observed in eyes undergoing iDose TR plus iStent infinite or canaloplasty with/without cataract surgery.
conclusionThe iDose TR travoprost implant combined with either iStent infinite implantation or canaloplasty was associated with significant reductions in IOP and topical IOP-lowering medications in most subgroups, with or without concurrent cataract surgery. These data support the shift to an interventional glaucoma paradigm and the utilization of multimodal therapy for glaucoma management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.